Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2021 · $858,966 — PROJECT SUMMARY A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). Here, we propose to leverage three recent discoveries from our groups to generate novel envelope (Env) immunogens that target the V1V2 region of the trimer…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2021 · $3,242,006 — Neutralizing antibodies are likely to be required for an effective HIV-1 vaccine. However, few candidate vaccines efficiently elicit broadly neutralizing antibodies (bNAbs) following vaccination. Recently, the VRC working group has elicited fusion peptide-directed bNAbs in guinea pigs and non-human …
Mehul Shamal Suthar · EMORY UNIVERSITY · 2021 · $757,655 — Humoral immunity is an essential component of the immune response to flavivirus infection. Primary infection generates a robust neutralizing antibody response that mediates viral control and protection. It is becoming increasingly apparent that secondary infection with a closely related flavivirus s…
Sina A Gharib · UNIVERSITY OF WASHINGTON · 2021 · $758,287 — PROJECT SUMMARY Melioidosis, a tropical infection commonly manifesting as acute pneumonia and sepsis in humans, is caused by the Gram-negative Tier 1 select agent Burkholderia pseudomallei and represents a global public health threat with an estimated 165,000 cases and 89,000 deaths annually worldwi…
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2021 · $802,998 — PROJECT SUMMARY Studying Natural SIV Reservoirs and Human Zoonotic Risk, we discovered in the last funding period that certain strains of SIV infecting Old World monkeys and African apes share unexpected antigenic cross- reactivity with HIV-1 in the functionally important V1V2 region of the envelope…
Galit Alter · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $348,242 — Abstract The robust protection conferred by emerging EUA approved SARS-CoV-2 vaccines represents a critical milestone in COVID-19 vaccine development. However, the emergence of variants has inspired renewed concern related to the protective efficacy of currently approved vaccines, which lose neutra…
David M Allman · UNIVERSITY OF PENNSYLVANIA · 2021 · $243,750 — Project summary Plasma cells that secrete antibodies against self-antigens pose a considerable threat to human health. Moreover, because many plasma cells are exceptionally long-lived, strategies are needed to deplete long-lived plasma cells (LLPCs) that secrete pathogenic antibodies. This project c…
Robbie B Mailliard · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2021 · $788,164 — ABSTRACT The CDC recommends that persons living with HIV (PWH) be vaccinated against SARS-CoV-2. However, there are minimal scientific data to support this important public health principle in relation to ongoing immune dysfunction and chronic comorbidities and the persistent HIV reservoir in antire…
Daniel Pearce Depledge · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $562,370 — 7. PROJECT SUMMARY / ABSTRACT Chemical modification of mRNA provides a powerful means to dynamically alter gene expression in eukaryotes via epitranscriptomic changes. In particular, methylation of adenosine at the N6 position (m6A) constitutes the most widespread internal base modification to mRNA.…
Emily K. Moser · UNIVERSITY OF FLORIDA · 2021 · $162,000 — PROJECT SUMMARY/ABSTRACT The NIH estimates that up to 23.5 million Americans suffer from autoimmune disease, driven in large part by germinal center (GC)-derived pathologic autoantibodies. GC B cells undergo iterative rounds of somatic hypermutation of B cell receptor (BCR) genes, and selection bas…
BRUNO DE BEZERRIL ANDRADE · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $695,679 — PROJECT SUMMARY Recent studies from our group have reported a peripheral blood correlate of risk (COR) transcriptional signature that identified individuals with incipient (asymptomatic) TB who progressed to active (symptomatic) TB disease within 12 months. We have also identified human genetic poly…
Clarence Buddy Creech · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $614,901 — Program Director/Principal Investigator (Last, First, Middle): Creech, Clarence B Supplement Abstract Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults This project supports specific aims 2…
Genevieve Giny Fouda Amou ou · DUKE UNIVERSITY · 2021 · $854,272 — Abstract As of March 2021, SARS-CoV-2 has caused more than 50 million infections and 2 million deaths, constituting an unprecedented pandemic in the modern world. While infected individuals rapidly develop IgG responses against the viral Spike after infection, some studies have indicated that indivi…
Peter B. Gilbert · FRED HUTCHINSON CANCER RESEARCH CENTER · 2021 · $2,034,708 — Project Abstract This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of the COVID-19 vaccine trial entitled “A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequen…
Sean PJ Whelan · WASHINGTON UNIVERSITY · 2021 · $561,330 — This application is to extend a MERIT award to study RNA synthesis in minus-strand RNA viruses. Nonsegmented negative-sense (NNS) RNA viruses include some of the most significant human pathogens that are an ongoing threat to US public health. For measles, mumps and rabies there are licensed vaccines…
Mark Bathe · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2021 · $370,098 — PROJECT SUMMARY/ABSTRACT COVID-19 has emerged from SARS-CoV-2 within the course of several months to spread worldwide as a deadly pandemic, with the number of deaths approaching one-half million worldwide. While over one hundred vaccines are currently in development, and several already in human cli…
LOUISA A STARK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2021 · $54,000 — As COVID-19 vaccines become more widely available, vaccine hesitancy is rapidly becoming one of the major barriers to achieving herd immunity to the SARS-CoV-2 virus in the US population. Lack of accurate scientific information is one of the multiple factors contributing to this hesitancy. To addres…
MIKELL PAIGE · GEORGE MASON UNIVERSITY · 2021 · $498,998 — PROJECT SUMMARY mRNA vaccines have received emergency authorization approval for Covid-19 and are under development for several other infectious diseases. The mRNA-encoded immunogen in these vaccines is delivered inside a lipid nanoparticle (LNP) that comprises four lipids, the most important being …
Esteban Daniel Erben · RBHS-NEW JERSEY MEDICAL SCHOOL · 2021 · $198,750 — PROJECT SUMMARY Trypanosoma brucei causes African trypanosomiasis in humans and livestock. In the mammalian infectious Bloodstream-Form (BF) stage, T. brucei expresses a single species of Variant Surface Glycoprotein (VSG) genes from over 2,500 VSG repertoire with a potential of switching to a diffe…
Jordan Green · JOHNS HOPKINS UNIVERSITY · 2021 · $204,688 — PROJECT SUMMARY Multiple sclerosis (MS) is the leading cause of non-traumatic disability in young adults in the United States. In MS, the immune system attacks autoantigens in the myelin sheath of the central nervous system (CNS), leading to neurological degeneration, and there is currently no cure…